Higher SHMT2 expression correlates with a worse prognosis or an aggressive phenotype in oral squamous cell carcinoma [63], bladder cancer [64], gastrointestinal tumors [65] and other cancers. Here, SHMT2 is linked to digestive system neoplasm.